BACKGROUND: Cushing syndrome (CS) secondary to ectopic adrenocorticotropic hormone (ACTH) secretion (EAS) has been described in association with a variety of tumors. The current experience with this syndrome was based on a few case series and individual case reports. Limited data were available about the tumors associated with CS-EAS in a cancer center setting. In this report, the authors have described their experience with CS-EAS at The University of Texas MD Anderson Cancer Center to further enhance the current understanding and management of this syndrome. METHODS: This was a retrospective review of 43 patients with CS-EAS who were diagnosed between 1979 and 2009 at The University of Texas MD Anderson Cancer Center. RESULTS: Different neuroendocrine tumors were associated with CS-EAS. Twenty-one patients (48.9%) had tumors located in the chest cavity, with bronchial carcinoid and small cell lung cancer representing the 2 most common causes. The ACTH source remained occult in 4 patients (9.3%) despite extensive workup. Clinical presentation varied, and the classic features of CS were not evident in some patients. Death occurred in 27 patients (62.8%), and the median overall survival was 32.2 months. Major morbidities included new-onset or worsening hyperglycemia (77%), symptomatic venous thromboembolism (14%), and infections (23%). CONCLUSIONS: In patients with CS-EAS who attended a comprehensive cancer center, tumors originating in the chest cavity were the leading tumors associated with this syndrome. The authors suspect that CS-EAS is under reported because of the atypical presentation in some patients. Thus, they suggest careful evaluation of patients with neuroendocrine tumors to avoid missing coexisting CS-EAS.
BACKGROUND:Cushing syndrome (CS) secondary to ectopic adrenocorticotropic hormone (ACTH) secretion (EAS) has been described in association with a variety of tumors. The current experience with this syndrome was based on a few case series and individual case reports. Limited data were available about the tumors associated with CS-EAS in a cancer center setting. In this report, the authors have described their experience with CS-EAS at The University of Texas MD Anderson Cancer Center to further enhance the current understanding and management of this syndrome. METHODS: This was a retrospective review of 43 patients with CS-EAS who were diagnosed between 1979 and 2009 at The University of Texas MD Anderson Cancer Center. RESULTS: Different neuroendocrine tumors were associated with CS-EAS. Twenty-one patients (48.9%) had tumors located in the chest cavity, with bronchial carcinoid and small cell lung cancer representing the 2 most common causes. The ACTH source remained occult in 4 patients (9.3%) despite extensive workup. Clinical presentation varied, and the classic features of CS were not evident in some patients. Death occurred in 27 patients (62.8%), and the median overall survival was 32.2 months. Major morbidities included new-onset or worsening hyperglycemia (77%), symptomatic venous thromboembolism (14%), and infections (23%). CONCLUSIONS: In patients with CS-EAS who attended a comprehensive cancer center, tumors originating in the chest cavity were the leading tumors associated with this syndrome. The authors suspect that CS-EAS is under reported because of the atypical presentation in some patients. Thus, they suggest careful evaluation of patients with neuroendocrine tumors to avoid missing coexisting CS-EAS.
Authors: J Lindholm; S Juul; J O Jørgensen; J Astrup; P Bjerre; U Feldt-Rasmussen; C Hagen; J Jørgensen; M Kosteljanetz; L Kristensen; P Laurberg; K Schmidt; J Weeke Journal: J Clin Endocrinol Metab Date: 2001-01 Impact factor: 5.958
Authors: Brooke Swearingen; Laurence Katznelson; Karen Miller; Steven Grinspoon; Arthur Waltman; David J Dorer; Anne Klibanski; Beverly M K Biller Journal: J Clin Endocrinol Metab Date: 2004-08 Impact factor: 5.958
Authors: Bregje Van Zaane; Erfan Nur; Alessandro Squizzato; Olaf M Dekkers; Marcel Th B Twickler; Eric Fliers; Victor E A Gerdes; Harry R Büller; Dees P M Brandjes Journal: J Clin Endocrinol Metab Date: 2009-05-19 Impact factor: 5.958
Authors: E Gomard-Mennesson; P Sève; E De La Roche; S Collardeau-Frachon; C Lombard-Bohas; C Broussolle Journal: Rev Med Interne Date: 2008-03-04 Impact factor: 0.728
Authors: Lilah F Morris; Rachel S Harris; Denái R Milton; Steven G Waguespack; Mouhammed A Habra; Camilo Jimenez; Rena Vassilopoulou-Sellin; Jeffrey E Lee; Nancy D Perrier; Elizabeth G Grubbs Journal: Surgery Date: 2013-12 Impact factor: 3.982
Authors: Agrons Michelle M; Corey T Jensen; Mouhammed Amir Habra; Christine O Menias; Akram M Shaaban; Nicolaus A Wagner-Bartak; Alicia M Roman-Colon; Khaled M Elsayes Journal: Br J Radiol Date: 2017-07-14 Impact factor: 3.039
Authors: José Manuel Cameselle-Teijeiro; José Antonio Mato Mato; Ovidio Fernández Calvo; Jesús García Mata Journal: Mol Diagn Ther Date: 2018-04 Impact factor: 4.074